Clinical Trials Logo

Lymphedema clinical trials

View clinical trials related to Lymphedema.

Filter by:

NCT ID: NCT04575636 Completed - Clinical trials for Lymphedema of Upper Limb

MRL in the Upper Extremity

Start date: September 10, 2020
Phase: N/A
Study type: Interventional

Objective: The aim of this study is to examine the feasibility and applicability of the MRL protocol for the upper extremity in Maastricht University Medical Center, and to examine the differences of the lymphatic system between lymphedema patients and healthy volunteers. Study design: An explorative study of an MRL protocol for the upper extremity in Maastricht University Medical Center+. Study population: There are two study groups. The first group (n=10) consists of patients with secondary lymphedema in the upper extremity. The second group (n=10) consists of healthy volunteers. Intervention (if applicable): All participants will undergo an MRL examination with the same protocol, developed in a previous 'proof of principle' study, in the Maastricht University Medical Center+. After localizer scans, a T2-weighted sequence is used. Then a T1-weighted sequence will be made before the injection of contrast. After the injection of the contrast agent a T1-weighted sequences of the upper and lower arm are performed alternately. Main study parameters/endpoints: The primary outcome is to determine the feasibility and applicability of the MRL protocol by evaluating the images of the upper extremity in patients with secondary lymphedema and healthy subjects. The secondary outcome is to assess the value of MRL in staging lymphedema.

NCT ID: NCT04570722 Completed - Breast Cancer Clinical Trials

Ipsilateral Peripheral Intravenous Access Procedures (The iPIVAP Study)

iPIVAP
Start date: September 20, 2021
Phase: N/A
Study type: Interventional

This pilot study will examine facilitators and barriers that impact staff uptake for implementation of practice change involving ipsilateral IV insertion in patients with axillary lymphadenectomy/dissection in a single radiology center.

NCT ID: NCT04568005 Completed - Lymphedema Clinical Trials

Evaluation of Lymphedema Patients Status During Covid-19 Pandemic

Start date: June 1, 2020
Phase:
Study type: Observational [Patient Registry]

The pandemic, which started in China at the end of 2019, appeared in our country in a short time. Most hospitals and physicians were only concerned with the treatment of these patients. One of the most victimized patient groups in this duration was lymphedema patients who were in need of continuous follow-up and rehabilitation at necessary periods, but were also at risk in terms of covid-19 infection and could not go to hospitals unless necessary. The treatment of both primary and secondary lymphedema patients has been interrupted or delayed. This process has affected the health status, treatment processes and quality of life of the lymphedema patient group. The current situation may have caused them anxiety and depression as a result of infection fear. In this study, we aimed to evaluate the treatment processes, health status, coronavirus phobia, anxiety, and depression states of the lymphedema patients .

NCT ID: NCT04552938 Completed - Lymphedema Clinical Trials

LVA on Serum Profiling in Patients With Lymphedema

Start date: April 11, 2018
Phase:
Study type: Observational

The correlation between oxidative stress and increased lymphedematous limb volume lacks supporting evidence. Lymphedema patients are prone to cellulitis. This study aims to investigate the link between oxidative stress, limb volume, and cellulitis after supermicrosurgical lymphaticovenous anastomosis (LVA).

NCT ID: NCT04541290 Completed - Clinical trials for Breast Cancer Lymphedema

Tacrolimus as Treatment of Breast Cancer-Related Lymphedema

Start date: September 22, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

BACKGROUND Breast cancer-related lymphedema is a severe and life-long side-effect to breast cancer treatment. The condition increases the risk of infections and decreases health-related quality of life (HR-QOL) in patients. No prophylactic or curative treatment is currently available for this condition. CD4+-cells plays a critical role in the development of lymphedema. The cells facilitate inflammation and fibrosis formation in the subcutaneous tissue which inhibits lymphatic regeneration. Tacrolimus is an immunosuppressive and anti-inflammatory macrolide that targets the CD4+-cells. Tacrolimus as treatment of lymphedema has already shown promising results in animal studies. Tacrolimus has the potential to cure an otherwise uncurable and life-long side-effect of BC and will therefore benefit a large number of patients who suffers from BCRL. AIM To assess the effect of Tacrolimus treatment on breast cancer-related lymphedema METHOD Study design A pilot study with a planned inclusion of 20 patients with a 12 month follow-up period. The purpose of this study is to assess the effect of tacrolimus treatment on lymphedema and HR-QOL. Results are attained from objective measures and questionnaires. The patients will be seen at a consultation prior to the treatment start and then 3 times hereafter (at 3, 6 and 12 months) as follow up consultations where effect of treatment is evaluated. Primary endpoint: - Arm volume measured with water displacement test. Secondary endpoints: - Arm volume measured with measuring tape and calculated with volume of a cone formula - Patient-reported outcome measured through the Danish versions of , LYMPH-ICF, DASH and SF-36 questionnaires - Bioimpedance - Lymphangiography Primary- and secondary endpoint data will be collected at each of the 3 consultations (prior to treatment and 3 and 6 months after the treatment start). CLINICAL IMPACT This will be the first clinical pharmacological study on regarding treatment of lymphedema with Tacrolimus. This study will test the feasibility and efficacy of Tacrolimus ointment in a population of breast cancer patients who have developed lymphedema. The study may lead to a routine clinical implementation of tacrolimus ointment to patients diagnosed with Lymphedema. Regardless of the outcome, the study will benefit the patients and future research in the field of lymphedema.

NCT ID: NCT04536064 Enrolling by invitation - Clinical trials for Description of an Effective Surgical Strategy to Treat Cancer Related Lymphedema, a High Incidence Pathology

COMBINATION OF LYMPHATICO-VENULAR ANASTOMOSIS AND LIPOSUCTION IN TREATING LYMPHEDEMA

Start date: February 22, 2021
Phase:
Study type: Observational

- cooperation of an International team with many years of experience in surgical management of lymphedema - description of an effective surgical strategy to treat cancer-related lymphedema, a high incidence pathology - the combination of LVA and liposuction guarantees long lasting results

NCT ID: NCT04522648 Recruiting - Breast Cancer Clinical Trials

Prospective Surveillance for Breast Cancer-Related Lymphedema

PROTECT
Start date: January 4, 2021
Phase: N/A
Study type: Interventional

This randomized trial will test the effect of a prospective surveillance program for early detection and subclinical management of breast cancer-related lymphedema on the prevalence of chronic lymphedema.

NCT ID: NCT04482855 Completed - Clinical trials for Head and Neck Cancer

Low-Level Laser in Head and Neck Chronic Lymphedema

Start date: August 19, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effect of low-level laser treatment (LLLT) on the severity of lymphedema, symptom burden, functional status, and quality of life in HNC survivors.

NCT ID: NCT04465253 Completed - Lymphedema Clinical Trials

Remotivation Process for Improving Adherence to Lymphedema Treatment Programs in Patients With Breast Cancer-Related Lymphedema

Start date: April 19, 2019
Phase: N/A
Study type: Interventional

This trial studies how well the Remotivation Process in an occupational therapy program works in improving adherence to lymphedema treatment programs in patients with breast cancer-related lymphedema. Lymphedema treatment programs are well developed and effective, but adherence to these programs are an issue. The Remotivation Process is a series of techniques that helps guide discussions between occupational therapists and their patients based on their level of motivation. This study uses the Remotivation Process by gathering patients' thoughts about their experience with lymphedema and occupational therapy services to determine their motivation and learn about the barriers they face in order to improve adherence to these programs.

NCT ID: NCT04457375 Completed - Clinical trials for Lymphedema, Secondary

Skin Biophysical Measures for Assessing Head and Neck Cancer-Related External Lymphedema

Start date: January 16, 2020
Phase:
Study type: Observational

Selected measurements in healthy persons of skin tissue dielectric constant as reference values for subsequent use to evaluate patients with head and neck lymphedema.